Literature DB >> 35128639

A large pragmatic trial is the right solution for testing anti-amyloid therapies for Alzheimer's disease.

M Maria Glymour1, Vincent Mor2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35128639      PMCID： PMC9106885          DOI： 10.1111/jgs.17695

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN： 0002-8614            Impact factor:   7.538


× No keyword cloud information.
  9 in total

Review 1.  Essential Ingredients and Innovations in the Design and Analysis of Group-Randomized Trials.

Authors:  David M Murray; Monica Taljaard; Elizabeth L Turner; Stephanie M George
Journal:  Annu Rev Public Health       Date:  2019-12-23       Impact factor: 21.981

2.  Association between enrollment factors and incident cognitive impairment in Blacks and Whites: Data from the Alzheimer's Disease Center.

Authors:  Carey E Gleason; Derek Norton; Megan Zuelsdorff; Susan F Benton; Mary F Wyman; Naomi Nystrom; Nickolas Lambrou; Hector Salazar; Rebecca L Koscik; Erin Jonaitis; Fabu Carter; Brieanna Harris; Alexander Gee; Nathaniel Chin; Frederick Ketchum; Sterling C Johnson; Dorothy F Edwards; Cynthia M Carlsson; Walter Kukull; Sanjay Asthana
Journal:  Alzheimers Dement       Date:  2019-10-07       Impact factor: 21.566

Review 3.  Selecting and Improving Quasi-Experimental Designs in Effectiveness and Implementation Research.

Authors:  Margaret A Handley; Courtney R Lyles; Charles McCulloch; Adithya Cattamanchi
Journal:  Annu Rev Public Health       Date:  2018-01-12       Impact factor: 21.981

4.  Alzheimer amyloid hypothesis lives on.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2016-12-29       Impact factor: 84.694

5.  An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM.

Authors:  Daniela J Conrado; William S Denney; Danny Chen; Kaori Ito
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-29       Impact factor: 2.745

6.  What the Aducanumab Approval Reveals About Alzheimer Disease Research.

Authors:  Jennifer J Manly; M Maria Glymour
Journal:  JAMA Neurol       Date:  2021-11-01       Impact factor: 18.302

7.  Life expectancy with and without dementia in persons with mild cognitive impairment in the community.

Authors:  Sanne S Mooldijk; Amber Yaqub; Frank J Wolters; Silvan Licher; Peter J Koudstaal; M Kamran Ikram; M Arfan Ikram
Journal:  J Am Geriatr Soc       Date:  2021-10-18       Impact factor: 7.538

Review 8.  Recruitment and retention of underrepresented populations in Alzheimer's disease research: A systematic review.

Authors:  Andrea L Gilmore-Bykovskyi; Yuanyuan Jin; Carey Gleason; Susan Flowers-Benton; Laura M Block; Peggye Dilworth-Anderson; Lisa L Barnes; Manish N Shah; Megan Zuelsdorff
Journal:  Alzheimers Dement (N Y)       Date:  2019-11-19

9.  Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis.

Authors:  Sarah F Ackley; Scott C Zimmerman; Willa D Brenowitz; Eric J Tchetgen Tchetgen; Audra L Gold; Jennifer J Manly; Elizabeth Rose Mayeda; Teresa J Filshtein; Melinda C Power; Fanny M Elahi; Adam M Brickman; M Maria Glymour
Journal:  BMJ       Date:  2021-02-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.